Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG

Crespo, Javier; Andrade, Raúl J.; Parras, Fernando Alberca de Las; Balaguer, Francesc; Acosta, Manuel Barreiro‐de; Bujanda, Luís; Gutiérrez, Ana; Jorquera, Francisco; Iglesias‐García, Julio; Sánchez-Yagüe, Andrés; Calleja, José Luís

doi:10.1016/j.gastre.2020.04.001

Cited by 10 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, the IBD patient should carefully self-monitor for possible signs of COVID-19, especially fever, respiratory symptoms or diarrhoea. 5 The risk of complications in patients with IBD will depend on the degree of activity of the disease, with it being higher in active patients. 8 Immunosuppressive medication could also affect how COVID-19 develops.…”

Section: What Should An Ibd Patient Living With a Confirmed Or Possibmentioning

confidence: 99%

“…In cases in which SARS-CoV-2 has been detected where the patient has stable IBD, the recommendation is to delay the administration of biological drugs and the restart of immunosuppressants for at least two weeks. 5 , 19 , 20 In patients who develop symptoms secondary to the infection, the immunosuppressive therapy should not be reinstated until the symptoms have completely resolved. A PCR test on nasopharyngeal exudate or serology could be indicated prior to restarting therapy and in patients who need to go to the day hospital, but in most cases this is not currently applicable.…”

Section: When Can Biological or Immunosuppressive Therapy Be Restartementioning

confidence: 99%

“…At the most dramatic points of the epidemic peak (2–3 weeks in March, depending on the geographic area), endoscopy was limited to cases with high suspicion of IBD, severe signs and symptoms and suggestive laboratory data, and patients with ulcerative colitis and severe flare-up to obtain biopsies to rule out reactivation of CMV infection. 5 Now that the situation has improved somewhat, the indications for endoscopic investigations have been expanded and include situations with a high risk of recurrence, recent high-grade dysplasia, or a poor response to certain treatments and involving a significant change in management.…”

Section: Is Urgent Endoscopy Necessary During the Covid-19 Outbreak? mentioning

confidence: 99%

“…The Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) [Spanish Working Group on Crohn’s Disease and Ulcerative Colitis] has carried out a large number of initiatives in this field, including publishing its recommendations on the management of these patients. 5 The aim of this document is to continue with the recommendations established by GETECCU and, in collaboration with the Grupo Enfermero de Trabajo en EII (GETEII) [Nursing Working Group on IBD], answer some of the most common practical questions on the care of people with IBD which have been raised in our clinics over the first months (February–April 2020) of the SARS-CoV-2 pandemic.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February–April 2020)

Marín-Jiménez¹,

Zabana²,

Rodríguez‐Lago³

et al. 2020

Gastroenterología y Hepatología (English Edition)

Self Cite

View full text Add to dashboard Cite

COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was described in China in late 2019. There are currently more than three million diagnosed cases, constituting a pandemic which has caused a worldwide crisis. The devastating effects of this infection are due to its highly contagious nature and although mild forms predominate, in absolute values, the rates for severe forms and mortality are very high. The information on the characteristics of the infection in inflammatory bowel disease is of special interest, as these patients have higher attendance at health centres, which may increase their risk of infection. Furthermore, the treatments used to control the inflammatory activity may modify the disease course of COVID-19. The Spanish Working Group on Crohn’s Disease and Ulcerative Colitis and the Spanish Nurses Working Group on Inflammatory Bowel Disease have prepared this document as a practical response to some common questions about the treatment of these patients.

show abstract

Section: What Should An Ibd Patient Living With a Confirmed Or Possibmentioning

confidence: 99%

Section: When Can Biological or Immunosuppressive Therapy Be Restartementioning

confidence: 99%

Section: Is Urgent Endoscopy Necessary During the Covid-19 Outbreak? mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February–April 2020)

Marín-Jiménez¹,

Zabana²,

Rodríguez‐Lago³

et al. 2020

Gastroenterología y Hepatología (English Edition)

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result, the different scientific associations, including the Asociación Española para el Estudio del Hígado (AEEH), American associations (AASLD) and European associations (EASL), have prepared position statements to design the guidelines that the different hepatology units should follow at present and in the next few months ( Table 1 ). 46 , 49 , 50 …”

Section: Introductionmentioning

confidence: 99%

COVID-19 and liver disease: An update

Téllez

Mateos

2020

Gastroenterología y Hepatología (English Edition)

View full text Add to dashboard Cite

Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)

Vives

Binefa

Vidal

et al. 2022

Preventive Medicine

View full text Add to dashboard Cite

The COVID-19 pandemic caused the suspension at all levels of the Catalan FIT-based CRC screening program on March 12, 2020. Screening invitations to FIT were resumed on September 1, 2020. We aimed to assess the short-term impact of the pandemic and describe strategies implemented to minimize harm by the disruption of the FIT-based CRC screening in the Metropolitan Area of Barcelona. We analyzed participation rate, colonoscopy adherence, time intervals to colonoscopy, detection rates, and advanced-stage cancers in 2019 and 2020. To identify perceived distress levels during the suspension of the screening we conducted a phone interview. As a result of the suspension, 43% of the individuals due for screening did not receive their invitation by December 31, 2020. A percent decrease of 5.1% in participation and of 8.9% in colonoscopy adherence among invitees between January–March was observed, with a recovery to 2019 levels when the screening activities were restarted. The time interval between a positive test to colonoscopy was longer in 2020 than in 2019. A decrease in advanced neoplasia rate and an increase in later stages of CRC were also observed. Individuals with a positive test did not report higher levels of perceived distress compared to those with a negative test. Although the disruption of screening had a temporary impact on participation and colonoscopy adherence, timing delay continues and a large backlog in the invitation of the target population remains. Thus, it is critical to implement strategies to minimize the long-term effects.

show abstract

Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG

Cited by 10 publications

References 33 publications

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February–April 2020)

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February–April 2020)

COVID-19 and liver disease: An update

Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)

Contact Info

Product

Resources

About